A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

• Complete Remission Rate by Independent Review Group [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
• Duration of Objective Response by Kaplan-Meier Analysis [ Time Frame: up to 17.5 months ] [ Designated as safety issue: No ]
  Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.
• Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis [ Time Frame: up to 17.5 months ] [ Designated as safety issue: No ]
  Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.
• Progression-free Survival by Kaplan-Meier Analysis [ Time Frame: up to 17.5 months ] [ Designated as safety issue: No ]
  Time from start of study treatment to disease progression per independent review group or death due to any cause.
• Overall Survival [ Time Frame: up to 17.5 months ] [ Designated as safety issue: No ]
  Time from start of study treatment to date of death due to any cause.
• Adverse Events by Severity, Seriousness, and Relationship to Treatment [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
  Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
• Hematology Laboratory Abnormalities >/= Grade 3 [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
  Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
• Chemistry Laboratory Abnormalities >/= Grade 3 [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
  Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
• Area Under the Curve [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin
• Maximum Serum Concentration [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin
• Time of Maximum Serum Concentration [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

• Duration of response, progression-free survival, overall survival. [ Time Frame: Every 3 months until death or study closure ] [ Designated as safety issue: No ]
• Incidence of adverse events and laboratory abnormalities [ Time Frame: Through 1 month following last dose ] [ Designated as safety issue: Yes ]
• PK profile [ Time Frame: Every 2 or 3 weeks ] [ Designated as safety issue: No ]

This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.

• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Non-Hodgkin

Inclusion Criteria:

• Patients with relapsed or refractory systemic ALCL who have previously received front line chemotherapy.
• Documented anaplastic lymphoma kinase (ALK) status.
• Histologically-confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.
• Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
• Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.
• At US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.

Exclusion Criteria:

• Previous treatment with brentuximab vedotin.
• Previously received an allogeneic transplant.
• Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible).
• Known cerebral/meningeal disease.